Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX-0593 vs crizotinib in ALK-positive advanced NSCLC
CTR20191231Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iruplinalkib in ALK-positive non-small cell lung cancer, sponsored by Qilu Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
iruplinalkib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20191231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191231.